Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.
about
Targeting FGFR in Squamous Cell Carcinoma of the Lung.Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.The role of Cediranib in ovarian cancer.Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.
P2860
Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Pharmacokinetics and tolerabil ...... ients with hepatic impairment.
@en
type
label
Pharmacokinetics and tolerabil ...... ients with hepatic impairment.
@en
prefLabel
Pharmacokinetics and tolerabil ...... ients with hepatic impairment.
@en
P2093
P1433
P1476
Pharmacokinetics and tolerabil ...... tients with hepatic impairment
@en
P2093
Carla M L van Herpen
Ingrid M E Desar
Kathryn H Brown
Maja J A de Jonge
Marcelo Marotti
P304
P356
10.1097/CAD.0B013E32835BD1D2
P50
P577
2013-02-01T00:00:00Z